Aarti Pharmalabs announced its Q2 2025 revenue of ₹41,728.78 lakhs during a board meeting held on November 9, 2025. The company's financial results for the quarter and half-year ended September 30, 2025, were approved following a review by the Audit Committee. The revenue reflects an increase from the previous quarter's revenue of ₹37,531.06 lakhs. The financial results, including the Profit and Loss Statement, Statement of Assets and Liabilities, and Cash Flow Statement, are now available on the company’s website, complying with the SEBI's listing regulations.

In terms of expenses, Aarti Pharmalabs reported a total of ₹37,873.82 lakhs for the quarter, resulting in a profit before tax of ₹4,169.82 lakhs. The company's net profit after tax was recorded at ₹3,092.91 lakhs. Compared to the previous quarter, where the net profit was ₹5,122.08 lakhs, this represents a decline in profitability. The board meeting commenced at 10:00 a.m. and concluded at 12:30 p.m., confirming that all necessary approvals were obtained during this session.

The results also indicate an operational trend with a consolidated revenue of ₹41,833.48 lakhs for the same quarter. Despite facing challenges in the market, Aarti Pharmalabs continues to focus on its single segment, Pharmaceuticals, and aims to enhance its operational performance moving forward. The company’s commitment to transparency and compliance is evident as it continues to meet regulatory requirements and communicate effectively with its stakeholders.